TORPENZ™ (everolimus)
www.torpenz.com
www.torpenz.com
Torpenz (everolimus) is approved for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Torpenz is also approved for the treatment of adult and pediatric patients 1 year of age and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. In addition, Torpenz is approved for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with anastrazole.